tbuckley/cabot-search huggingface dataset:
Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B
Authors: Gi-Ae Kim, Seung Won Choi, Seungbong Han, Young-Suk Lim
Journal: Clinical and Molecular Hepatology (2024)

Serum hepatitis B virus (HBV) DNA levels and non-invasive liver fibrosis scores are significantly associated with hepatocellular carcinoma (HCC) risk in chronic hepatitis B (CHB) patients. Nonetheless, the relationship between HBV DNA levels and liver fibrosis scores is unclear. A historical cohort comprising 6,949 non-cirrhotic Korean CHB patients without significant alanine aminotransferase elevation was investigated. The association of HBV DNA levels with the aspartate aminotransferase to platelet ratio index (APRI) and fibrosis (FIB)-4 score at baseline was analyzed using general linear models. In HBeAg-negative patients (n=4,868), HBV DNA levels correlated linearly with both APRI and FIB-4 scores. In contrast, in HBeAg-positive patients (n=2,081), HBV DNA levels correlated inversely with both APRI and FIB-4 scores. Across the entire cohort, a significant non-linear parabolic relationship was identified between HBV DNA levels and fibrosis scores, independent of age and other covariates. Notably, moderate viral loads (6-7 log10 IU/mL) corresponded to the highest APRI and FIB-4 scores (p<0.001). Over a median 10-year follow-up, 435 patients (6.3%) developed HCC. Higher APRI scores ≥0.5 and FIB-4 scores ≥1.45 were significantly associated with elevated HCC risk (p<0.001 for both). HBV DNA level remained a significant predictive factor for HCC development, even after adjusting for APRI or FIB-4 scores. HBV viral load is significantly correlated with APRI and FIB-4 scores, and is also associated with HCC risk independent of those scores in CHB patients. These findings suggest that HBV DNA level is associated with hepatocarcinogenesis through both direct and indirect pathways.
Protecting public health in Europe: building trust in a challenging world
Authors: Pamela Rendi-Wagner
Journal: Eurosurveillance (2024)

Preview this article: Protecting public health in Europe: building trust in a challenging world, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/29/29/eurosurv-29-29-1-1.gif
The European Society of Cardiology Working Group on Coronary Pathophysiology and Microcirculation
Authors: Edina Cenko, Marija Zdravkovic, Dimitris Tousoulis, Teresa Padro, Ana Djordjevic-Dikic, Ines Drenjancevic, Alfredo R Galassi, Ingrid Fleming, Daphne Merkus, Laurent M Riou, Marija Zdravkovic, Charalambos Antoniades, Dirk J Duncker, Tomasz J Guzik, Davor Milicic, Marija Vavlukis
Journal: Cardiovascular Research (2024)
Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective study
Authors: Pablo Ryan, Jorge Valencia, Guillermo Cuevas, Rafael Amigot-Sanchez, Isidoro Martínez, Jeffrey V Lazarus, Felipe Pérez-García, Salvador Resino
Journal: Eurosurveillance (2024)

Background People who use drugs (PWUD) are a key target population to reduce the burden of hepatitis C virus (HCV) infection. Aim To assess risk factors and temporal trends of active HCV infection in PWUD in Madrid, Spain. Methods We conducted a retrospective study between 2017 and 2023, including 2,264 PWUD visiting a mobile screening unit. Data about epidemiology, substance use and sexual risk behaviour were obtained through a 92-item questionnaire. HCV was detected by antibody test, followed by RNA test. The primary outcome variable was active HCV infection prevalence, calculated considering all individuals who underwent RNA testing and analysed by logistic regression adjusted by the main risk factors. Results Of all participants, 685 tested positive for anti-HCV antibodies, and 605 underwent RNA testing; 314 had active HCV infection, and 218 initiated treatment. People who inject drugs (PWID) were identified as the main risk group. The active HCV infection rate showed a significant downward trend between 2017 and 2023 in the entire study population (23.4% to 6.0%), among PWID (41.0% to 15.0%) and PWUD without injecting drug use (7.0% to 1.3%) (p &lt; 0.001 for all). These downward trends were confirmed by adjusted logistic regression for the entire study population (adjusted odds ratio (aOR): 0.78), PWID (aOR: 0.78), and PWUD non-IDU (aOR: 0.78). Conclusions Our study demonstrates a significant reduction in active HCV infection prevalence among PWUD, particularly in PWID, which suggests that efforts in the prevention and treatment of HCV in Madrid, Spain, have had an impact on the control of HCV infection.
HIV-infected Latin American asylum seekers in Madrid, Spain, 2022: A prospective cohort study from a major gateway in Europe
Authors: Pablo Ryan, Samuel Manzano, Neda Deihim-Rahampour, Guillermo Cuevas, Laura Martin-Gonzalez, Alicia Gonzalez-Baeza, Pedro Torres, Jeffrey V Lazarus, Juan Torres-Macho, Jorge Valencia, Matilde Sanchez-Conde
Journal: Eurosurveillance (2024)

Background Recent migration trends have shown a notable entry of Latin American asylum seekers to Madrid, Spain. Aim To characterise the profile of asylum-seeking Latin American migrants who are living with HIV in Spain and to outline the barriers they face in accessing HIV treatment. Methods A prospective cohort study was conducted between 2022 and 2023 with a 6-month follow-up period. Latin American asylum seekers living with HIV were recruited mainly from non-governmental organisations and received care at an HIV clinic in a public hospital in Madrid. Results We included 631 asylum seekers. The primary countries of origin were Colombia (30%), Venezuela (30%) and Peru (18%). The median age was 32 years (interquartile range (IQR): 28–37), and 553 (88%) were cis men of which 94% were men who have sex with men. Upon their arrival, 49% (n = 309) lacked social support, and 74% (n = 464) faced barriers when attempting to access the healthcare system. Upon entry in Europe, 500 (77%) participants were taking antiretroviral therapy (ART). At their first evaluation at the HIV clinic, only 386 (61%) had continued taking ART and 33% (n = 209) had detectable plasma HIV-1 RNA levels. Six months later, 99% took ART and 98% had achieved an undetectable viral load. Conclusions Latin American asylum seekers living with HIV in Madrid, Spain encountered barriers to healthcare and to ART. One-third of these individuals presented detectable HIV viral load when assessed in the HIV clinic, highlighting this as an important public health issue.
Sitting Time and Its Interaction With Physical Activity in Relation to All-Cause and Heart Disease Mortality in U.S. Adults With Diabetes
Authors: Wen Dai, Sandra S. Albrecht
Journal: Diabetes Care (2024)

OBJECTIVE To evaluate whether associations between sitting time and all-cause and heart disease mortality are modified by physical activity in adults with diabetes. RESEARCH DESIGN AND METHODS Data came from 6,335 U.S. adults with diabetes from National Health and Nutrition Examination Survey 2007–2018 (baseline), with mortality follow-up through 2019. Sitting time and moderate to vigorous physical activity (MVPA) were self-reported. Cox models were adjusted for sociodemographics, lifestyle factors, and medical conditions. RESULTS Over a median follow-up of 5.9 years, 1,278 all-cause and 354 heart disease deaths were documented (mean age, 59.6 years; 48.3% female). Longer sitting time was associated with greater all-cause and heart disease mortality risk in inactive (MVPA &amp;lt;10 min/week) or insufficiently active (MVPA 10 to &amp;lt;150 min/week) adults with diabetes, but not in active adults (MVPA ≥150 min/week) (all-cause mortality: P = 0.003 for interaction; heart disease mortality: P = 0.008 for interaction). CONCLUSIONS In adults with diabetes, meeting guideline-recommended physical activity may offset the elevated all-cause and heart disease mortality risk associated with excessive sitting time.
AI-Driven neurosurgery with sora: applications and complexities
Authors: Xinjie Zhang, Jiao Wang, Jinhong Li, Jinhai Gou
Journal: International Journal of Surgery (2024)

aDepartment of Pediatric Neurosurgery, West China Second University Hospital, Sichuan University; Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, Sichuan, China bDepartment of Epidemiology, College of Preventive Medicine, Third Military Medical University, Chongqing, China cDepartment of Obstetrics and Gynaecology, Centre for Reproductive Medicine, West China Second University Hospital; Sichuan Provincial Key Laboratory of Development and Related Diseases of Women and Children, Chengdu , Sichuan, China dDepartment of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, 610041, Sichuan, China Data available on request from the authors. Xinjie Zhang, Jiao Wang, Jinhong Li, Contribute equally as first authors. The data that support the findings of this study are available from the corresponding author, upon reasonable request. Published online ■ ■ *Corresponding author. Address: Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Ren Min Nan Lu Avenue 20, Sichuan, Chengdu 610041, China. Email: [email protected] (J. Gou). This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/
Liver stiffness progression in biopsy-proven metabolic dysfunction–associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study
Authors: Daniel Q. Huang, Laura A. Wilson, Cynthia Behling, Maral Amangurbanova, David E. Kleiner, Kris V. Kowdley, Srinivasan Dasarathy, Norah A. Terrault, Anna Mae Diehl, Naga Chalasani, Brent A. Neuschwander-Tetri, Arun J. Sanyal, James Tonascia, Rohit Loomba
Journal: Hepatology (2024)

There are limited data on the progression of liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) in people with type 2 diabetes mellitus (T2DM) versus those without T2DM in biopsy-proven metabolic dysfunction-associated steatotic liver disease. We examined LSM progression in participants with T2DM versus those without T2DM in a large, prospective, multicenter cohort study.
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in Kupffer cells in mice
Authors: Juanjuan Li, Yinghong Zheng, Zhenzhen Duan, Qingye Zeng, Jin Qu, Jincheng Zhang, Jiao Liu, Wenlong Shang, Xixi Tao, Tingting Yu, Xinzhi Li, Lifu Wang, Liming Yang, Deping Kong, Ying Yu
Journal: Hepatology (2024)

The liver possesses a remarkable regenerative capacity in response to injuries or viral infections. Various growth factors and cytokines are involved in regulating liver regeneration. Prostaglandin D 2 , a pro-resolution lipid mediator, is the most abundant hepatic prostanoid. However, the role of prostaglandin D 2 in the injury-induced liver regeneration remains unclear.
Epigenetic heterogeneity hotspots in human liver disease progression
Authors: Ryan A. Hlady, Xia Zhao, Louis Y. El Khoury, Ryan T. Wagner, Aesis Luna, Kien Pham, Nikolaos T. Pyrosopoulos, Dhanpat Jain, Liguo Wang, Chen Liu, Keith D. Robertson
Journal: Hepatology (2024)

Disruption of the epigenome is a hallmark of human disease, including liver cirrhosis and HCC. While genetic heterogeneity is an established effector of pathologic phenotypes, epigenetic heterogeneity is less well understood. Environmental exposures alter the liver-specific DNA methylation landscape and influence the onset of liver cancer. Given that currently available treatments are unable to target frequently mutated genes in HCC, there is an unmet need for novel therapeutics to prevent or reverse liver damage leading to hepatic tumorigenesis, which the epigenome may provide.
CX3CR1+ macrophages interact with hepatic stellate cells to promote hepatocellular carcinoma through CD8+ T cell suppression
Authors: Jong-Min Jeong, Sung Eun Choi, Young-Ri Shim, Hee-Hoon Kim, Young-Sun Lee, Keungmo Yang, Kyurae Kim, Min Jeong Kim, Katherine Po Sin Chung, Seok-Hwan Kim, Jin-Seok Byun, Hyuk Soo Eun, Won-Il Jeong
Journal: Hepatology (2024)

Background and Aims: HSCs contribute to HCC progression by regulating multiple factors. However, the entire immunoregulatory functions of HSCs are still obscure. Here, we aim to investigate whether HSCs impose CX 3 CR1 + macrophages to protumorigenic properties in the peritumoral area. Approach and Results: In single-cell RNA-sequencing analysis of patients with HCC, a subpopulation of macrophages specifically expressed Arg1 and Cx3cr1 in the peritumoral area and were highly enriched with retinol metabolism–related genes. Flow cytometry analysis showed significantly increased frequencies of CD14 + CD11b + HLA-DR − macrophages with CX 3 CR1 in the HCC adjacent region where α-smooth muscle actin–expressing activated hepatic stellate cells (aHSCs) showed colocalized expression of CX 3 CL1. Accordingly, in tumor-bearing mice, Cx3cl1 mRNA expression was notably increased in aHSCs within the adjacent HCC, where infiltration of CX 3 CR1 + Ly6C + macrophages was mostly observed with decreased CD8 + T cells. In adoptive transfer and in vitro coculture of myeloid cells, we demonstrated that CX 3 CR1 + Ly6C + macrophages migrated and highly expressed arginase-1 by interacting with retinoid-enriched aHSCs in the adjacent HCC. Direct treatment of retinoids or coculturing with retinol-storing mouse aHSCs or human LX-2 cells significantly increased arginase-1 expression in CX 3 CR1 + Ly6C + macrophages and human blood CD14 + cells, leading to the suppression of CD8 + T-cell proliferation. Moreover, genetic deficiency of CX 3 CR1 in myeloid cells or pharmacological inhibition of retinol metabolism remarkably attenuated HCC development. Conclusions: We showed that CX 3 CR1 + Ly6C + macrophages migrate and interact with aHSCs in the peritumoral region where retinoids induce arginase-1 expression in CX 3 CR1 + Ly6C + macrophages, subsequently depriving CD8 + T cells of arginine and promoting HCC.
Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD
Authors: Sander Lefere, Antonella Mosca, Christian Hudert, Ellen Dupont, Emer Fitzpatrick, Eirini Kyrana, Anil Dhawan, Laura Kalveram, Andrea Pietrobattista, Anja Geerts, Ruth De Bruyne
Journal: Hepatology (2024)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent pediatric liver disease, yet accurate risk scores for referral of children/adolescents with suspected clinically significant liver fibrosis are currently lacking.
Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL
Authors: Hagop Kantarjian, Nicholas J. Short, Fadi G. Haddad, Nitin Jain, Xuelin Huang, Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Tapan M. Kadia, Naval Daver, Kelly Chien, Yesid Alvarado, Guillermo Garcia-Manero, Ghayas C. Issa, Rebecca Garris, Cedric Nasnas, Lewis Nasr, Farhad Ravandi, Elias Jabbour
Journal: Journal of Clinical Oncology (2024)

JCO
Significance of Measurable Residual Disease in Adult Philadelphia Chromosome–Positive ALL: A GRAAPH-2014 Study
Authors: Rathana Kim, Yves Chalandon, Philippe Rousselot, Jean-Michel Cayuela, Françoise Huguet, Marie Balsat, Marie Passet, Patrice Chevallier, Yosr Hicheri, Emmanuel Raffoux, Thibaut Leguay, Sylvain Chantepie, Sébastien Maury, Sandrine Hayette, Françoise Solly, Thorsten Braun, Bernard De Prijck, Victoria Cacheux, Celia Salanoubat, Laure Farnault, Isabelle Guibaud, Mathilde Lamarque, Lauris Gastaud, Emilie Lemasle, Eolia Brissot, Emmanuelle Tavernier, Karine Bilger, Alban Villate, Jean Soulier, Carlos Graux, Véronique Lhéritier, Hervé Dombret, Nicolas Boissel, Emmanuelle Clappier
Journal: Journal of Clinical Oncology (2024)

PURPOSE BCR::ABL1 quantification is widely regarded as the standard for monitoring measurable residual disease (MRD) in Philadelphia chromosome–positive (Ph+) ALL. However, recent evidence of BCR::ABL1 multilineage involvement questions the significance of BCR::ABL1 MRD. We aimed to define the prognostic role of MRD as assessed by BCR::ABL1 or lymphoid-specific immunoglobulin/T-cell receptor ( IG/TR) gene markers. PATIENTS AND METHODS We conducted BCR::ABL1 and IG/TR quantification after each treatment cycle in 264 patients treated in the GRAAPH-2014 trial, which used four cycles of reduced-intensity chemotherapy with nilotinib, followed by hematopoietic stem-cell transplantation (HSCT). RESULTS Comparing BCR::ABL1 and IG/TR MRD revealed residual BCR::ABL1-positive non-ALL cells in 98 (43%) of 228 patients, defining multilineage Ph+ ALL. Despite poorer BCR::ABL1 responses, patients with multilineage Ph+ ALL had similar disease-free survival (DFS; hazard ratio [HR], 0.83 [95% CI, 0.49 to 1.41]; P = .50). Although BCR::ABL1 response failed to predict outcomes, IG/TR positivity (≥0.01%) was strongly associated with lower DFS (after cycle 2, HR, 2.49 [95% CI, 1.40 to 4.40]; P = .002; after cycle 4, HR, 4.13 [95% CI, 1.82 to 9.38]; P = .001). In multivariable analysis, both IG/TR positivity after cycle 2 and initial WBC count ≥30 × 10 9 /L predicted poorer DFS, enabling to define a high-risk group having a 4-year DFS of 56.5% compared with 87.6% (HR, 3.72 [95% CI, 1.93 to 7.15]; P &lt; .001). Moreover, allogeneic HSCT significantly improved DFS in the high-risk group (HR, 0.33 [95% CI, 0.18 to 0.60]; P &lt; .001), whereas the standard-risk group had favorable outcomes regardless of allogeneic HSCT. CONCLUSION Our findings challenge the significance of BCR::ABL1 monitoring in adult Ph+ ALL and demonstrate the prognostic role of IG/TR MRD. This study provides a framework for using MRD to guide treatment strategies in adults with Ph+ ALL.
Estrogen Plus Progestin and Colorectal Cancer: Long-Term Findings From the Women's Health Initiative Randomized Clinical Trial
Authors: Rowan T. Chlebowski, Aaron K. Aragaki, Kathy Pan, Juhua Luo, Thomas E. Rohan, Karen C. Johnson, Jean Wactawski-Wende, Su Yon Jung, Qian Xiao, Sayeh Lavasani, JoAnn E. Manson, Michael S. Simon
Journal: Journal of Clinical Oncology (2024)

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We report long-term colorectal cancer findings from the Women's Health Initiative trial where 16,608 postmenopausal women with a uterus were randomly assigned to daily conjugated equine estrogen (CEE) 0.625 mg, plus medroxyprogesterone acetate (MPA) 2.5 mg, or placebo. When intervention ended after 5.6 years, although there were 44% fewer colorectal cancers in the intervention group (43 v 72, P = .003), the cancers were more commonly lymph node–positive (59.0% v 29.4%, P = .003). Now after cumulative 24-year follow-up, with 431 colorectal cancers, CEE plus MPA no longer influenced colorectal cancer incidence (215 [0.15, annualized rate %] v 216 [0.15], hazard ratio [HR], 0.95 [95% CI, 0.79 to 1.15]). Although not statistically significant, there were more colorectal cancer deaths with CEE plus MPA (87 [0.049] v 69 [0.041] deaths, HR, 1.20 [95% CI, 0.87 to 1.65], P = .26). Vaginal bleeding (54.1% v 5.2% at 6 months) and breast changes were more frequent in the intervention group. After adjusting for postrandomization vaginal bleeding and breast changes, bowel examinations were significantly delayed in intervention group participants ( P = .005), potentially contributing to diagnostic delay. Taken together, the findings suggest no clinically meaningful benefit for about 5 years of CEE plus MPA use on colorectal cancer outcome.
Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk Disease
Authors: Jack P. Gleeson, Andrea Knezevic, Maria Bromberg, Sujata Patil, Joel Sheinfeld, Brett S. Carver, Manjit Bains, David R. Jones, Dean F. Bajorin, George J. Bosl, Deaglan J. McHugh, Samuel A. Funt, Robert J. Motzer, Darren R. Feldman
Journal: Journal of Clinical Oncology (2024)

Paclitaxel, ifosfamide, and cisplatin (TIP) is an established salvage regimen for germ cell tumors (GCT) on the basis of a phase II trial, but efficacy on a large patient cohort including patients with unfavorable risk features and long-term outcomes has not been reported. Herein, we report updated treatment efficacy and long-term follow-up with TIP.
Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis
Authors: Benjamin Koh, Jieling Xiao, Cheng Han Ng, Michelle Law, Shyna Zhuoying Gunalan, Pojsakorn Danpanichkul, Vijay Ramadoss, Benedix Kuan Loon Sim, En Ying Tan, Chong Boon Teo, Benjamin Nah, Margaret Teng, Karn Wijarnpreecha, Yuya Seko, Mei Chin Lim, Hirokazu Takahashi, Atsushi Nakajima, Mazen Noureddin, Mark Muthiah, Daniel Q. Huang, Rohit Loomba
Journal: Hepatology (2024)

Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of liver disease. Dynamic changes in MRI proton-density-fat fraction (PDFF) are associated with MASH resolution. We aimed to determine the relative efficacy of therapeutic agents for reducing hepatic fat, assessed by MRI-PDFF.
Acute kidney injury in severe alcohol-associated hepatitis treated with anakinra plus zinc or prednisone
Authors: Kavish R. Patidar, Wanzhu Tu, Thomas G. Cotter, Douglas A. Simonetto, Amon Asgharpour, Muhammad Y. Jan, Qing Tang, Yunpeng Yu, Yang Li, Moyinoluwa Taiwo, Prashanth Thevkar Nagesh, Srinivasan Dasarathy, Patrick S. Kamath, Craig J. McClain, Naga Chalasani, Gyongyi Szabo, Ramon Bataller, Mack Mitchell, Wajahat Z. Mehal, Laura E. Nagy, Vijay H. Shah, Samer Gawrieh, Arun J. Sanyal
Journal: Hepatology (2024)

In a recent trial, patients with severe alcohol-associated hepatitis treated with anakinra plus zinc (A+Z) had lower survival and higher acute kidney injury (AKI) rates versus prednisone (PRED). We characterize the clinical factors and potential mechanisms associated with AKI development in that trial.
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study
Authors: Collin M. Blakely, Anatoly Urisman, Matthew A. Gubens, Claire K. Mulvey, Greg M. Allen, Stephen C. Shiboski, Julia K. Rotow, Turja Chakrabarti, D. Lucas Kerr, Jacqueline V. Aredo, Bianca Bacaltos, Megan Gee, Lisa Tan, Kirk D. Jones, W. Patrick Devine, Robert C. Doebele, Dara L. Aisner, Tejas Patil, Erin L. Schenk, Trever G. Bivona, Jonathan W. Riess, Melissa Coleman, Johannes R. Kratz, David M. Jablons
Journal: Journal of Clinical Oncology (2024)

To assess the safety and efficacy of the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib as neoadjuvant therapy in patients with surgically resectable stage I-IIIA
Phase II trial of HER-Vaxx, a B cell peptide-based vaccine, in HER2-overexpressing advanced gastric cancer patients under platinum-based chemotherapy (HERIZON)
Authors: Joshua Tobias, Marina Maglakelidze, Zoran Andrić, Dinara Ryspayeva, Iurie Bulat, Ivan Nikolić, Zoran Petrovic, Tanuj Chawla, Rajnish Nagarkar, Erika Garner-Spitzer, Christoph C. Zielinski, Leslie Mi Ok. Chong, Bonnie Nixon, Nicholas J. Ede, Sharon Yavrom, Michael Kundi, Ursula Wiedermann
Journal: Clinical Cancer Research (2024)

A multicenter, randomized, open-label, phase II study (HERIZON; NCT02795988) was conducted to evaluate the clinical and immunologic efficacy of HER-Vaxx (IMU-131), a B-cell, peptide-based vaccine targeting HER2 overexpressed in 6% to 30% of gastroesophageal adenocarcinomas (GEA).